IFNA1 and neoplasm: Following a similar scheme for advanced-stage disease LNP treatment in the β-M model, we added IgG or β-PD1 to the regimen 3-days after LNP dose, which was determined based on enhanced IFN signaling at this timepoint, and harvested mice by 10.5-week timepoint or when moribund to assess and compare response, and also performed a survival study to determine long-term anti-tumor immunity (Figure 7e).